efpeglenatide
Peptideexperimental
Clinical trial activity
12 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
10
Phase 3
6
Phase 4
0
Earliest trial started Feb 1, 2010 (NCT01093729)
Timeline
Indications
Mechanism of action
- GlucagonAGONIST
GCG agonist
GLP1R agonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650470 ↗
Also known as
- hm11260c
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06174779 | Phase 3 | Dec 19, 2023 | Hanmi Pharmaceutical |
| NCT03770728 | Phase 3 | Jul 18, 2019 | Sanofi |
| NCT03713684 | Phase 3 | May 31, 2019 | Sanofi |
| NCT03684642 | Phase 3 | Sep 27, 2018 | Sanofi |
| NCT03496298 | Phase 3 | Apr 27, 2018 | Sanofi |
| NCT03353350 | Phase 3 | Dec 5, 2017 | Sanofi |
| NCT02081118 | Phase 2 | Feb 1, 2014 | Hanmi Pharmaceutical |
| NCT02075281 | Phase 2 | Feb 1, 2014 | Hanmi Pharmaceutical |
| NCT02057172 | Phase 2 | Jan 1, 2014 | Hanmi Pharmaceutical |
| NCT02059564 | Phase 1 | Dec 1, 2013 | Hanmi Pharmaceutical |
| NCT01452451 | Phase 2 | Dec 1, 2011 | Hanmi Pharmaceutical |
| NCT01093729 | Phase 1 | Feb 1, 2010 | Hanmi Pharmaceutical |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hanmi Pharmaceutical | For profit | 7 | 7 | 3 | 2010 |
| Sanofi | For profit | 5 | 5 | 1 | 2017 |
2 organizations
Page 1 / 1